Dagmar Wider

430 total citations
27 papers, 301 citations indexed

About

Dagmar Wider is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Dagmar Wider has authored 27 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 15 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Dagmar Wider's work include Multiple Myeloma Research and Treatments (19 papers), Chemokine receptors and signaling (6 papers) and Protein Degradation and Inhibitors (6 papers). Dagmar Wider is often cited by papers focused on Multiple Myeloma Research and Treatments (19 papers), Chemokine receptors and signaling (6 papers) and Protein Degradation and Inhibitors (6 papers). Dagmar Wider collaborates with scholars based in Germany, United States and Canada. Dagmar Wider's co-authors include Monika Engelhardt, Ralph Wäsch, Gabriele Ihorst, Marie Follo, Johannes M. Waldschmidt, Justus Duyster, Julia Schüler, Mihaela Zlei, Manik Chatterjee and Dominik Schnerch and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Dagmar Wider

24 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dagmar Wider Germany	10	164	144	141	83	33	27	301
Stefania Girlanda Italy	7	97 0.6×	70 0.5×	104 0.7×	69 0.8×	33 1.0×	9	249
Bauke de Boer Netherlands	9	132 0.8×	261 1.8×	67 0.5×	72 0.9×	37 1.1×	13	394
Manuela Gambella Italy	8	193 1.2×	181 1.3×	116 0.8×	61 0.7×	24 0.7×	13	283
L. T. F. Van De Locht Netherlands	9	108 0.7×	181 1.3×	66 0.5×	50 0.6×	41 1.2×	9	283
Derek Bouman Canada	8	129 0.8×	229 1.6×	71 0.5×	73 0.9×	64 1.9×	9	377
Lucia Di Marzo Italy	6	150 0.9×	178 1.2×	106 0.8×	49 0.6×	20 0.6×	7	277
John W. Wine United States	7	78 0.5×	184 1.3×	113 0.8×	226 2.7×	32 1.0×	9	393
Ayano Yurino Japan	6	136 0.8×	124 0.9×	113 0.8×	190 2.3×	34 1.0×	8	328
Forhad Ahmed United Kingdom	6	59 0.4×	113 0.8×	157 1.1×	196 2.4×	36 1.1×	9	380
Turner Kufe United States	6	128 0.8×	216 1.5×	164 1.2×	148 1.8×	10 0.3×	7	368

Countries citing papers authored by Dagmar Wider

Since Specialization

Citations

This map shows the geographic impact of Dagmar Wider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dagmar Wider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dagmar Wider more than expected).

Fields of papers citing papers by Dagmar Wider

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dagmar Wider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dagmar Wider. The network helps show where Dagmar Wider may publish in the future.

Co-authorship network of co-authors of Dagmar Wider

This figure shows the co-authorship network connecting the top 25 collaborators of Dagmar Wider. A scholar is included among the top collaborators of Dagmar Wider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dagmar Wider. Dagmar Wider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waldschmidt, Johannes M., Dagmar Wider, Johannes Jung, et al.. (2022). Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma. Journal of Cancer Research and Clinical Oncology. 148(5). 1045–1055. 11 indexed citations

Dold, Sandra Maria, Dagmar Wider, Marie Follo, et al.. (2021). Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients. Frontiers in Oncology. 11. 708231–708231. 7 indexed citations

Kreutmair, Stefanie, Andrea Schmidts, Gabriele Ihorst, et al.. (2018). APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells. Cellular and Molecular Life Sciences. 76(2). 369–380. 5 indexed citations

Dold, Sandra Maria, Dagmar Wider, Marie Follo, et al.. (2018). Minimal Residual Disease (MRD) Analysis Using Multiparametric Flow Cytometry (MFC) and Identification of Differences in Subpopulations Using Next Generation Sequencing (NGS) in the Bone Marrow (BM) of Multiple Myeloma (MM) Patients (pts). Blood. 132(Supplement 1). 3222–3222. 1 indexed citations

Müller, Stefan J., Dagmar Wider, Andreas Thomsen, et al.. (2017). Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach. Blood. 130. 1793–1793. 1 indexed citations

Waldschmidt, Johannes M., Anna Simon, Dagmar Wider, et al.. (2017). CXCL12 and CXCR7 are relevant targets to reverse cell adhesion‐mediated drug resistance in multiple myeloma. British Journal of Haematology. 179(1). 36–49. 59 indexed citations

Waldschmidt, Johannes M., Dagmar Wider, Stefan J. Müller, et al.. (2016). PIM1-Mediated CXCR4 Phosphorylation: A Potentially Class-Distinct Therapeutic Target of Next Generation Proteasome Inhibitors in Multiple Myeloma. Blood. 128(22). 2774–2774.

Keller, Alexander, Johannes M. Waldschmidt, Dagmar Wider, et al.. (2015). Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD). Blood. 126(23). 4260–4260. 1 indexed citations

Keller, Alexander, Johannes M. Waldschmidt, Dagmar Wider, et al.. (2015). Vorinostat (V), bortezomib (B), doxorubicin (Dox) and dexamethasone (Dex, VBDD) in relapsed or refractory multiple myeloma patients (pts): results of an open, non-comparative, phase I/II investigator initiated trial (IIT). Clinical Lymphoma Myeloma & Leukemia. 15. e276–e277.

10.

Schueler, Julia, Dagmar Wider, Gabrielle M. Siegers, et al.. (2015). Novel Patient Derived Multiple Myeloma Model Reflects Sensitivity Towards Anticancer Treatment in Multiple Myeloma Patients. Blood. 126(23). 3004–3004. 1 indexed citations

11.

Schueler, Julia, Dagmar Wider, Gabrielle M. Siegers, et al.. (2013). Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2Rγ(Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies. PLoS ONE. 8(11). e79939–e79939. 21 indexed citations

12.

Schüler, Julia, Dagmar Wider, Gabriele Ihorst, et al.. (2013). Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138‐downregulation and inhibition of migration through actin depolymerization. British Journal of Haematology. 161(1). 104–116. 33 indexed citations

13.

Schmidts, Andrea, et al.. (2012). Dissecting Stem Cell Proliferation and Differentiation in Association with the Central Cell Cycle Regulator APC/CCdh1. Blood. 120(21). 1236–1236. 1 indexed citations

14.

Wider, Dagmar, Julie Catusse, Dominik Schnerch, et al.. (2011). Multikinase Inhibitor Sorafenib Induces Apoptosis, CD138-Downregulation, Actin Depolymerization and Inhibition of M210B4-Triggered Chemotaxis in Multiple Myeloma Cell Lines and Synergyzes with Proteasome Inhibitor Bortezomib. Blood. 118(21). 2380–2380. 1 indexed citations

15.

Wider, Dagmar, et al.. (2011). Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: Association with disease characteristics and variation in different cell compartments. Leukemia Research. 35(9). 1265–1268. 7 indexed citations

16.

Hein, Manuel, Marie Follo, Dagmar Wider, et al.. (2010). Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome. Leukemia & lymphoma. 51(9). 1632–1642. 12 indexed citations

17.

Schüler, Julia, et al.. (2009). “Antitumor Activity of Novel Anti-MM Agents and Combinations, the Proteasome Inhibitor Bortezomib and Multikinase Inhibitor Sorafenib, Both Applied as Monotherapy and in Combination in NOD/SCID-IL2-Receptor-Gamma-chain−/− (NSG) Mice Using a Intratibial Tumor Dissemination approach”.. Blood. 114(22). 4912–4912. 1 indexed citations

18.

Zlei, Mihaela, et al.. (2007). Characterization of in vitro growth of multiple myeloma cells. Experimental Hematology. 35(10). 1550–1561. 35 indexed citations

19.

Guo, Yue, et al.. (2005). Effects of 5-aza-2′-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells. Leukemia. 20(1). 115–121. 19 indexed citations

20.

Fisch, Paul, Gabriele Köhler, Annette I. Garbe, et al.. (1996). Generation of antigen‐presenting cells for soluble protein antigens ex vivo from peripheral blood CD34⁺ hematopoietic progenitor cells in cancer patients. European Journal of Immunology. 26(3). 595–600. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact